



## Commercial/Healthcare Exchange PA Criteria

*Effective: November 2015*

**Prior Authorization:** Long-acting muscarinic antagonist/long-acting beta-agonist

**Products Affected:** Bevespi Aerosphere (glycopyrrolate and formoterol) Inhalation Aerosol; Utibron Neohaler (indacaterol and glycopyrrolate) inhalation capsule

**Medication Description:** LAMAs and LABAs have been associated with a reduced COPD exacerbation rate. Combining bronchodilators with different mechanisms of action may further improve patient symptoms with a lower risk of adverse events compared to increasing the dose of a single bronchodilator. Combination bronchodilators have a greater impact on patient reported outcomes and quality of life compared to monotherapies; however, more studies are needed to determine if combination therapy is more effective than monotherapy at preventing exacerbations.

**Covered Uses:** Chronic obstructive pulmonary disease (COPD)

**Exclusion Criteria:** N/A

**Required Medical Information:**

1. Diagnosis
2. Previous medications tried/failed

**Age Restrictions:** 18 years of age and older

**Prescriber Restrictions:** N/A

**Coverage Duration:** 12 months

**Other Criteria:**

- A. Patient has a diagnosis of COPD; AND
- B. Patient has had a documented trial and failure of both of the following medications:
  - Anoro Ellipta; AND
  - Stiolto Respimat

**References:**

1. Product Information: BEVESPI AEROSPHERE(TM) inhalation aerosol powder, glycopyrrolate and formoterol fumarate inhalation aerosol powder. AstraZeneca Pharmaceuticals LP (per FDA), Wilmington, DE, 2019.
2. Product Information: UTIBRON(R) NEOHALER(R) oral inhalation powder, indacaterol glycopyrrolate oral inhalation powder. Sunovion Pharmaceuticals Inc (per FDA), Marlborough, MA, 2019.

Last Rev. January 2021

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	11/2015
2	Policy Update	Removed Affected products from CCI Freedom Inhaler Policy and renamed policy, moved to new Template.	All	1/13/2020
3	Update	Policy now applies to Commercial lines of business	All	3/27/2020
4	Update	Updated policy to include CCI commercial and exchange lines of business  Annual Review	All	1/1/2021